TY - JOUR
T1 - Practical Application of Patient-Reported Health Status Measures for Transcatheter Valve Therapies
T2 - Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry
AU - Hejjaji, Vittal
AU - Cohen, David J.
AU - Carroll, John D.
AU - Li, Zhuokai
AU - Manandhar, Pratik
AU - Vemulapalli, Sreekanth
AU - Nelson, Adam J.
AU - Malik, Ali O.
AU - Mack, Michael J.
AU - Spertus, John A.
AU - Arnold, Suzanne V.
N1 - Funding Information:
Dr Cohen has received grant support and consulting income from Edwards Lifesciences, Medtronic, Abbott, and Boston Scientific; Dr Carroll is an investigator for the Placement of Aortic Transcatheter Valve (PARTNER) trial sponsored by Edwards Lifesciences and the low risk transcatheter aortic valve replacement (TAVR) versus Surgical Aortic Valve Replacement trial sponsored by Medtronic; Dr Vemulapalli has received grants/contracts from the American College of Cardiology, Society of Thoracic Surgeons, National Institutes of Health, Patient-Centered Outcomes Research Institute, Food and Drug Administration (Nest cc), Boston Scientific & Abbott Vascular. Also received consulting fees from Boston Scientific, Janssen, HeartFlow; Dr Mack has served as a coprimary investigator for Edwards Lifesciences, study chair for Medtronic and trial coprimary investigator for Abbott; Dr Spertus has received consulting income from United Healthcare, Bayer, and Novartis; research grants from Abbott, Novartis, and American College of Cardiology. The other authors report no conflicts.
Funding Information:
The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry is an initiative of the Society of Thoracic Surgeons and the American College of Cardiology. This research was supported by the American College of Cardiology’s National Cardiovascular Data Registry (NCDR). The views expressed in this article represent those of the authors and do not necessarily represent the official views of the NCDR or its associated professional societies identified at CVQuality.ACC.org/NCDR. The study sponsors were not involved in the design and conduct of the study; analysis and interpretation of the data; preparation of the article; or decision to submit the article for publication. Drs Hejjaji and Malik are supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number T32HL110837.
Publisher Copyright:
© 2021 American Heart Association, Inc.
PY - 2021/3
Y1 - 2021/3
N2 - Background: Health status assessment is essential for documenting the benefit of transcatheter aortic valve replacement (TAVR) or transcatheter mitral valve repair on patients' symptoms, function, and quality of life. Health status can also be a powerful marker for subsequent clinical outcomes, but its prognostic importance around the time of both TAVR and transcatheter mitral valve repair has not been fully defined. Methods: Among 73 699 patients who underwent transfemoral TAVR or transcatheter mitral valve repair between 2011 and 2018 (mean age, 81.9±7.0 years, 53% men, 92% TAVR), we constructed sequential models examining the association of health status (as assessed with the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score; KCCQ-OS) at baseline, 30 days, change from baseline to 30 days, and combinations of these assessments with death and heart failure (HF) hospitalization from 30 days to 1 year. Results: Although higher baseline KCCQ-OS and 30-day KCCQ-OS scores were each associated with lower risk of death and HF hospitalization (in individual models and in a model including both measures), the 30-day KCCQ-OS was most predictive (death: hazard ratio, 0.89 per 5-point increase [95% CI, 0.89-0.90]; HF hospitalization: hazard ratio, 0.91 [95% CI, 0.90-0.91]). The 30-day KCCQ-OS also was most predictive when included in a separate model with change in KCCQ from baseline to 30 days. Similar findings were noted for the outcomes of death and of HF hospitalization, unadjusted and adjusted for patient factors. All interaction terms between procedure type and KCCQ were not significant, suggesting that health status provided similar prognostic information in both procedures. Conclusions: The patient's assessment of their health status immediately before and 30 days after TAVR and transcatheter mitral valve repair is associated with subsequent risk of death and HF hospitalization, with the 30-day assessment being most strongly associated with outcomes. Our findings support the routine use of KCCQ data as a prognostic tool.
AB - Background: Health status assessment is essential for documenting the benefit of transcatheter aortic valve replacement (TAVR) or transcatheter mitral valve repair on patients' symptoms, function, and quality of life. Health status can also be a powerful marker for subsequent clinical outcomes, but its prognostic importance around the time of both TAVR and transcatheter mitral valve repair has not been fully defined. Methods: Among 73 699 patients who underwent transfemoral TAVR or transcatheter mitral valve repair between 2011 and 2018 (mean age, 81.9±7.0 years, 53% men, 92% TAVR), we constructed sequential models examining the association of health status (as assessed with the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score; KCCQ-OS) at baseline, 30 days, change from baseline to 30 days, and combinations of these assessments with death and heart failure (HF) hospitalization from 30 days to 1 year. Results: Although higher baseline KCCQ-OS and 30-day KCCQ-OS scores were each associated with lower risk of death and HF hospitalization (in individual models and in a model including both measures), the 30-day KCCQ-OS was most predictive (death: hazard ratio, 0.89 per 5-point increase [95% CI, 0.89-0.90]; HF hospitalization: hazard ratio, 0.91 [95% CI, 0.90-0.91]). The 30-day KCCQ-OS also was most predictive when included in a separate model with change in KCCQ from baseline to 30 days. Similar findings were noted for the outcomes of death and of HF hospitalization, unadjusted and adjusted for patient factors. All interaction terms between procedure type and KCCQ were not significant, suggesting that health status provided similar prognostic information in both procedures. Conclusions: The patient's assessment of their health status immediately before and 30 days after TAVR and transcatheter mitral valve repair is associated with subsequent risk of death and HF hospitalization, with the 30-day assessment being most strongly associated with outcomes. Our findings support the routine use of KCCQ data as a prognostic tool.
KW - Death
KW - Health status
KW - Heart failure
KW - Hospitalization
KW - Transcatheter aortic valve replacement
UR - http://www.scopus.com/inward/record.url?scp=85103227930&partnerID=8YFLogxK
U2 - 10.1161/CIRCOUTCOMES.120.007187
DO - 10.1161/CIRCOUTCOMES.120.007187
M3 - Article
C2 - 33596663
AN - SCOPUS:85103227930
SN - 1941-7705
VL - 14
JO - Circulation: Cardiovascular Quality and Outcomes
JF - Circulation: Cardiovascular Quality and Outcomes
IS - 3
M1 - e007187
ER -